INM

InMed Pharmaceuticals earns an Underweight rating, with a composite score in the mid-30s and low conviction at 1/5. The regulatory pillar provides the strongest contribution at 49, supported by a 50 jurisdiction posture and an 80 enforcement subscore. Market follows at 40, although the absence of an available quote limits price-based confirmation from institutional pricing feeds. Editorial contributes 30, reflecting baseline news and briefing subscores without recent CIN newsroom coverage. Fundamentals rank last at 21, with a respectable gross-margin contribution overwhelmed by contracting revenue, deeply negative operating profitability, limited scale, and weak cash-runway scoring. The pillar mix places the company firmly in the Underweight band.

Licensed fundamentals data show year-over-year revenue contraction of roughly 26%, while gross margin stands near 35%. That gross-profit profile fails to translate into operating leverage: operating margin is approximately negative 163%, net loss is about $8.5 million, and EBITDA is negative by roughly $7.8 million. Market capitalization is below $9 million, producing no contribution from the scale tier, while the cash-burn ratio approaches 0.90 and the cash-runway subscore sits at 15. Those figures support the stated stretched financial condition; negative EBITDA and the bottom-line loss keep funding pressure central to the thesis. Primary regulatory filings show no recorded events across either the latest three-month or six-month windows, and no latest filing date is available. The resulting cadence subscore of 25 offsets the stronger enforcement profile, where no enforcement hits support the 80 subscore.

The clearest potential catalyst sits within regulatory, the highest-scoring pillar. A renewed sequence of timely primary regulatory filings could lift the weak cadence component, improve transparency around operating progress, and reinforce the existing absence of enforcement hits. Such improvement would carry greater rating relevance than editorial activity because regulatory already has the strongest pillar base, while fundamentals remain constrained by revenue decline, severe operating losses, negative EBITDA, and stretched finances. The single most important signal to watch is the appearance of a current primary regulatory filing that restores measurable filing cadence.